Arcturus Therapeutics 

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The company is headquartered in San Diego, California and currently employs 72 full-time employees. The firm owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The firm's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.